Cambridge, UK 25th April 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Paul Beastall as Chair of the Board of Directors. Paul was previously a Non-Executive Director at Evonetix, having joined the Board in 2020. His new appointment to Chair will see him take a more involved role in guiding product development strategy. This announcement follows the Company’s recent patent grant for technology enabling thermally-controlled DNA synthesis. Paul has over 20 years’ experience in product…

Marks & Clerk are delighted to announce that Associates Graham McGlashan and Erik Rõuk will be attending the 7th International XR Conference, taking place in Lisbon next month. The event is taking place in partnership with The Manchester Metropolitan University, ISCTE - Instituto Universitario de Lisboa and the International Association of Immersive Technology Innovation. Graham will be participating in a discussion about how the Metaverse is reshaping society and also leading a talk about trends in XR-related patent filings; so this is definitely not an event to be missed. For more…

Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has today been recognised with one of the UK’s most prestigious business awards – the Queen’s Award for Enterprise for International Trade. Cellomatics is one of 225 organisations nationally to be recognised with a prestigious Queen’s Award for Enterprise. Employing 15 people, Cellomatics was founded in 2015 and specialises in the development of bespoke bioassays across numerous therapeutic areas including oncology, immuno-oncology, immunology, inflammation and respiratory. Last year, the company reported year-on-…

Leading global drug development consultancy Boyds has bolstered its clinical team with the appointment of experienced pharmaceutical physician Dr Karen Mullen FFPM as Chief Medical Offer (CMO) and Vice President of Clinical and Medical Affairs. Karen joins Boyds from GlaxoSmithKline, with her most recent role being Country Medical Director for the UK and Ireland in which she led and managed a large medical department across clinical research, pharma, and vaccines. Karen’s previous roles at GSK include Head of Medical Affairs, Director of Vaccines, and Director of Metabolic Medicine. With…

Exciting One Nucleus and Future of Work Collaboration for Employer of Choice Series Cambridge UK: 26 April 2022 One Nucleus is delighted to announce a unique collaboration with the Future of Work Institute to host 5 one-hour seminars for our Employer of Choice Series through 2022. Aligning employer and employee needs, values and aspirations in the workplace produces many opportunities irrespective of company size or business model. The purpose of this collaboration is to provide our members with real world insights, guidance, and best practices on becoming employers of choice in order to…

    One Nucleus Announce Exciting Collaboration with ProductLife Group on New Training Course: ‘Performance Evaluation & Post-Market Surveillance on Medical Devices & IVDs under MDR & IVDR’  Cambridge UK: 14 April 2022 As One Nucleus continues to develop its training portfolio to meet the needs of member and non-member companies and their employees, it is delighted to announce an exciting new collaboration with ProductLife Group (PLG). In a changing regulatory environment, this two-day online course is an opportunity for those knowledgeable in Medical Device…

Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING, INSULIN FOR DIABETES Cambridge, UK, 12 April 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled “AT278 (U500) – PK/PD and safety of rapid-acting concentrated insulin aspart”, has been selected for oral presentation at the upcoming 15th International Conference on Advanced Technologies and…

Cambridge, UK, 13th April 2022: Mursla, a novel multi-omics exosome characterisation company, is pleased to present its novel nanochip-based technology, as detailed in the pre-print* ‘An electro-optical bead-nanochip technology for the ultrasensitive and multi-dimensional detection of small extracellular vesicles and their markers’, published today. This technology is part of Mursla’s ExoPheno™ platform.   Key features of the technology include:   • Ultrasensitive detection of target exosomes and their markers. • Compatibility with clinical practices in a high throughput format. •…

AbbVie and We Are Pioneer Group launch Golden Ticket programme to help UK life science start-ups accelerate the delivery of life-changing innovations to patients ● Programme designed to help promising start-ups commercialise drug discovery and provide access to much-needed laboratory space ● 2021 was the highest year on record for investments into UK biotech and life sciences companies – who raised £4.5 billion ● Move demonstrates AbbVie’s and WAPG’s commitment to investing in the UK’s world-class life sciences sector LONDON - APR. 4, 2022 - AbbVie, the global research-driven…

AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.  Exosomes are small endosome derived lipid nanoparticles actively secreted by exocytosis in most living cells. Release of exosomes occurs either constitutively or upon induction, under both normal and pathological conditions, in a dynamic, regulated and functionally relevant manner. Isolated from diverse cell lines, Exosomes have been shown…